MEMBERS

Acquisition of U.S.-based Avista Technologies, Inc. and UK-based Avista Technologies (UK)Ltd.

Acquisition of TCRS Restaurants Sdn. Bhd. in Malaysia.

Acquisition of Grazper Technologies ApS in Denmark.

Investment and business alliance with Bloom Biorenewables SA in Switzerland.

Investment and capital/business alliance with Oishii Farm Corporation in the U.S.

Asset transfer of anti-inflammatory eye drops Flarex®, anti-fungal eye drops Natacyn®, anti-inflammatory/anti-infective eye drops TobraDex®ST, anti-allergy eye drops ZERVIATE®, and dry eye drops FRESHKOTE® to Harrow Health, Inc. (U.S.).

Acquisition of the high-purity semiconductor chemicals business in the Asia region (Japan, China, South Korea, Taiwan) from SACHEM, Inc. in the U.S.

Corporation for the Overseas Development of Japan’s ICT and Postal Services Inc. (JICT) : Investment in May Mobility, Inc in the U.S. alongside MUFG Bank, Ltd.

Execution of a Investment and Shareholders’ Agreement with Action Construction Equipment Ltd. for the Establishment of a Joint Venture in India.

Acquisition of German startup Plasmion GmbH.

Divestiture of its U.S. subsidiary Pentagon Technologies Group, Inc. to AEQUITA GmbH & Co. KG in Germany.

[Domestic & In-bound M&A/Private Equity/ TOB (Tender Offer Bids) & MBO/Defense against Activism & Hostile Takeover (Unsolicited Bids)]

Tender offer (TOB) for Maruman Corporation.

Privatization via Management Buyout (MBO) sponsored by Orchestra Private Equity.

Succession of a portion of Hitachi Plant Construction, Ltd.’s thermal power generation-related business via company split.

Capital and business alliance with ASO CORPORATION (third-party allotment) and self-tender offer against market purchases by CITY INDEX ELEVENTH CO., Ltd. (Chairman of the Special Committee) .

Sale of subsidiary Tokyo Yusoh Co., Ltd. to Central Tank Terminal Co., Ltd. (a KKR portfolio company).

Acquisition of all shares of Yamanaka Hutech Corporation, a manufacturer of high-purity chemicals for semiconductors.

Prior announcement (not executed) of a TOB for Tokyo Cosmos Electric shares by Bourns Japan Holdings LCC against shareholder proposals (Chairman of the Special Committee).

Capital and business alliance with MEDIA DO Co., Ltd.

Privatization via MBO sponsored by a CVC; consideration of a counter-proposal from Kohlberg Kravis Roberts & Co. L.P.

Tender offer (TOB) by Idemitsu Kosan Co., Ltd. for Fuji Oil Company, Ltd. (Chairman of the Special Committee for Fuji Oil Company, Ltd.).

Succession of the in-vitro diagnostics business to a newly established company and subsequent sale of all shares to Tokuyama Corporation.

Establishment of a joint venture (Cellafa Bioscience Inc.) with Astellas Pharma Inc. to develop and provide a manufacturing platform for regenerative medicine products.

Introduction of a poison pill (takeover defense measures) following large-scale share purchases by CITY INDEX ELEVENTH CO., Ltd.(Chairman of the Special Committee).

Acquisition of shares in Nisseicom, Limited through its investment subsidiary SHIFT Growth Capital Inc.

Introduction of a poison pill (takeover defense measures) against large-scale share purchases involving "wolf pack tactics".

Proxy fight and shareholder meeting regarding a shareholder request to convene an extraordinary general meeting.

Pre-Announcement of Tender Offer by Nippon Yusen Kabushiki Kaisha to Take NS UNITED KAIUN KAISHA, LTD. Private, and Pre-Announcement of Self-Tender Offer by NS UNITED KAIUN KAISHA, LTD.

[Corporate Crisis Management]

Investigation as the Special Investigation Committee regarding inappropriate expense reimbursement involving management (Chairman of the Special Investigation Committee).

[Energy & Infrastructure Projects]

Support for investment in an offshore wind power project in Taiwan.

[Healthcare & Life Science]

Entered into a license agreement with ADC Therapeutics SA. (Switzerland) for the anti-CD19 antibody-drug conjugate "Loncastuximab tesirine".

Entered into an out-licensing agreement with Visiox Pharmaceuticals, Inc. (U.S.) for the product rights in the U.S. regarding the glaucoma and ocular hypertension treatment OMLONTI®.

Entered into an out-licensing agreement with Harrow Health, Inc. (U.S.) for the product rights in the U.S. regarding the vernal keratoconjunctivitis treatment Verkazia® and artificial tears Cationorm®Plus.

Entered into an exclusive license agreement with Vertex Pharmaceuticals Incorporated (U.S.) for the development and commercialization of "Povetacicept" in Japan and South Korea.